Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $29.56

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $29.56.

Several brokerages have commented on FDMT. Chardan Capital decreased their price target on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Barclays decreased their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. Bank of America cut their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a report on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Finally, Royal Bank Of Canada lowered their target price on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Decheng Capital LLC lifted its stake in shares of 4D Molecular Therapeutics by 0.5% in the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock valued at $2,228,000 after purchasing an additional 2,165 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in 4D Molecular Therapeutics by 7.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after buying an additional 2,925 shares during the period. PNC Financial Services Group Inc. lifted its position in 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after buying an additional 3,630 shares during the last quarter. Rhumbline Advisers lifted its position in 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after buying an additional 3,675 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in 4D Molecular Therapeutics by 30.1% during the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock worth $91,000 after buying an additional 3,783 shares during the period. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $3.84 on Wednesday. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93. The company has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $4.31. The firm has a market cap of $177.91 million, a P/E ratio of -1.21 and a beta of 2.84.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. On average, sell-side analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.